Plexxikon Inc. v. Novartis Pharmaceuticals Corporation

  1. December 12, 2023

    Novartis To Pay Daiichi $182M In Deal To End Appeal

    Novartis Pharmaceuticals has agreed to pay $182 million to Daiichi Sankyo subsidiary Plexxikon as part of a settlement in a patent infringement case over skin cancer drug Tafinlar after Novartis appealed a 2022 decision awarding Plexxikon $177.8 million, plus royalties.

  2. September 30, 2022

    $178M Verdict Against Novartis Stands But Can't Be Tripled

    A California federal judge has upheld a jury's $177.8 million infringement verdict against Novartis but overturned the jury's finding that the infringement of a Daiichi Sankyo unit's patents was willful.

  3. November 03, 2021

    Novartis Fights Enhanced Damages Bid After $178M Jury Loss

    Novartis says that it shouldn't have to pay enhanced damages after a jury hit the company with a $177.8 million verdict for selling a skin cancer drug that infringes two patents owned by a Daiichi Sankyo subsidiary.

  4. July 22, 2021

    Jury Hits Novartis With $178M Verdict In Drug Patent Fight

    A California federal jury hit Novartis with a $177.8 million verdict Thursday for selling a skin cancer drug that infringes two patents owned by a Daiichi Sankyo subsidiary, rejecting Novartis' arguments that the patents are invalid and awarding the entire sum the plaintiff sought.

  5. July 21, 2021

    Daiichi Sankyo Unit Seeks $178M From Novartis As Trial Ends

    Daiichi Sankyo subsidiary's counsel told a California federal jury during trial closings Wednesday that Novartis owes more than $177.8 million in royalties and fixed payments for infringing its skin cancer treatment patents, while Novartis' attorney argued that the patents are invalid and should never have been issued.

  6. July 19, 2021

    Novartis IP Expert Slams Rival's Royalties Estimate At Trial

    During a California federal jury trial Monday over claims Novartis owes a Daiichi Sankyo subsidiary royalties for infringing its skin cancer patents, Novartis' patent damages expert criticized the unit's $47.2 million royalties estimate and testified that any royalties should be $1.89 million at most.

  7. July 16, 2021

    Novartis' Expert Denies Rival Atty's Plagiarism Claim In IP Trial

    A computational chemist hired by Novartis testified to a California federal jury Friday that a Daiichi Sankyo subsidiary's drug patents are invalid for being too broad, while defending his credibility against opposing counsel's claim that his opinions were written by attorneys and "copied wholesale" from another ​report.

  8. July 15, 2021

    Novartis' Expert Accuses Rival's Atty Of Gaslighting In IP Trial

    A chemist hired by Novartis testified that a Daiichi Sankyo subsidiary's skin cancer treatment patents are invalid as either obvious or too vague, accusing opposing counsel of "gaslighting" him during a contentious examination in a California federal jury trial on Thursday.

  9. July 14, 2021

    Novartis Shorted Rival Up To $47M In IP Royalties, Jury Told

    An economist hired by a Daiichi Sankyo subsidiary testified during a California federal jury trial Wednesday that Novartis owes up to $47.2 million for selling a drug that infringes the subsidiary's skin cancer treatment patents, while Novartis' counsel pointed out the expert's calculations assume that the patents are valid.

  10. July 13, 2021

    Judge Tells Attys IP Testimony Is 'Dense,' But 'It's Your Case'

    A California federal judge presiding over a jury trial over claims Novartis infringed a Daiichi Sankyo subsidiary's billion-dollar skin cancer treatment patents questioned the usefulness of the day's "dense" trial testimony about chemistry and molecular structures, but told the attorneys, "It's your case."